Table 2.
Linear Mixed Effects Model: Effect of TDF Treatment on Creatinine and Creatinine Clearance
| Unadjusted Estimates | Adjusted Estimatesa | |||||||
|---|---|---|---|---|---|---|---|---|
| Coefficient b | 95% CI | P Value | Interactionc | Coefficient b | 95% CI | P Value | Interactionc | |
| Creatinine, mg/dL (n = 359) | ||||||||
| Average change per year | ||||||||
| With TDF treatment | 0.00 | .00 to .01 | .166 | .003 | 0.00 | −.01 to .01 | .674 | .003 |
| Without TDF treatment | 0.03 | .01 to.04 | <.001 | … | 0.02 | .01 to .03 | <.001 | … |
| Creatinine clearance, mL/min (n = 355) d | ||||||||
| Average change per year | ||||||||
| With TDF treatment | −2.2 | −3.0 to −1.5 | <.001 | .007 | −1.8 | −2.6 to −1.1 | <.001 | .007 |
| Without TDF treatment | −4.4 | −5.8 to −3.0 | <.001 | … | −4.0 | −5.5 to −2.6 | <.001 | … |
Abbreviation: TDF, tenofovir disoproxil fumarate.
a
Estimates adjusted for decompensated liver cirrhosis, age, and sex.
b
Marginal mean estimates extracted from the linear mixed effects model with random intercept.
c
P value from interaction between treatment and time, showing whether the coefficients differ between patients with and without TDF treatment.
d
Four missing values because of missing baseline body weight.